



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20, 31/445	A1	(11) International Publication Number: WO 99/09957 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/15237 (22) International Filing Date: 21 July 1998 (21.07.98) (30) Priority Data: 08/920,158 26 August 1997 (26.08.97) US (71) Applicant: HOECHST MARION ROUSSEL, INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: MACLAREN, David, D.; 5808 West 157th Street, Overland Park, KS 66223 (US). LEFLER, John, R.; 11306 W. 112th Terrace, Overland Park, KS 66210 (US). MINISH, Sharon, K.; 11323 E. 32nd Street, Independence, MO 64052 (US). (74) Agent: WILLE, Louis, J.; Hoechst Marion Roussel, Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALKANOL-DECONGESTANT		
(57) Abstract <p>The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising: (a) a first discrete zone made with Formulation (A) which comprises a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18 % to about 39 % by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of: (i) carnauba wax in an amount of about 59 % to about 81 % by weight of Formulation (A); and (ii) a suitable antiadherent in an amount of about 0.25 % to about 2.00 % by weight of Formulation (A); wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and (b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15 % to about 30 % by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of: (i) a cellulose diluent in an amount of about 27 % to about 73 % by weight of Formulation (B); (ii) pregelatinized starch in an amount of about 15 % to about 30 % by weight of Formulation (B); (iii) a suitable disintegrant in an amount of about 0.25 % to about 6.00 % by weight of Formulation (B); and (iv) a suitable lubricant in an amount of about 0.25 % to about 2.00 % by weight of Formulation (B); wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

10

PHARMACEUTICAL COMPOSITION FOR COMBINATION OF
PIPERIDINOALKANOL-DECONGESTANT

BACKGROUND OF THE INVENTION

15

It has been established that various piperidinoalkanol compounds are useful as antihistamines, antiallergy agents and bronchodilators as disclosed in U.S. Patent Nos. 3,878,217, 4,254,129 and 4,285,957. Several examples of formulations of these various piperidinoalkanol compounds are described below.

20

J. Domet and D. Shah describe in U.S. Patent No. 4,929,605, a pharmaceutical composition in solid unit dosage form, comprising, a therapeutically effective amount of a piperidinoalkanol compound, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable nonionic or cationic surfactant in an amount of from about 0.1% to about 6% by weight of the composition, and a pharmaceutically acceptable carbonate salt in an amount of from about 2% to about

25

50% by weight of the composition.

30

N. Webb and G. Hammer describe in U.S. Patent No. 4,996,061, a pharmaceutical composition in the form of a multiple-compression tablet comprising a discrete zone made from a formulation which provides sustained-release of a therapeutically effective decongestant amount of a sympathomimetic drug and a discrete zone made from a different formulation which provides immediate release of a therapeutically effective antihistaminic amount of a piperidinoalkanol and, optionally, a therapeutically effective decongestant amount of a sympathomimetic drug.

H. Schock, et al. describe in U.S. Patent No. 4,999,226 a multi-layered tablet containing an ibuprofen layer, a piperidinoalkanol antihistamine layer, and a layer or layers containing conventional pharmaceutical excipients which is interspersed between the ibuprofen and piperidinoalkanol layer and serves to physically separate them. It was disclosed by Schock et al. that attempts to formulate a two-layered tablet failed as a result of chemical degradation of the piperidinoalkanol in the presence of ibuprofen. In addition, attempts to retard this rate of degradation using anti-oxidants also failed.

T. Ortyl, et al. disclose in International Application No. WO 96/26726, published September 6, 1996, a pharmaceutical composition in solid unit dosage form comprising a piperidinoalkanol compound and at least one inert ingredient.

A number of products are currently available for the treatment of the symptomatology associated with ailments such as the common cold, seasonal rhinitis, sinus headaches, sinusitis, etc., which contain multiple therapeutic agents. Many of these products contain an antihistamine in combination with a sympathomimetic decongestant. Such combination products are convenient for the patient since they allow the patient to obtain relief from numerous symptoms without taking multiple medications.

An attempt was made to formulate a multiple-compression tablet containing the sympathomimetic drug, pseudoephedrine hydrochloride in sustained release form with the piperidinoalkanol, 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride, in immediate release form using a formulation similar to that disclosed by N. Webb and G. Hammer in U.S. Patent No. 4,996,061. However, this formulation failed as a result of unexpected and unacceptable cracking and unacceptable physical strength of the tablets on final compression.

In addition, an attempt was made to prepare a single compression tablet wherein pseudoephedrine hydrochloride sustained release beads and an immediate release form of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride were combined in a single layer tablet. However, this formulation also failed as some of the samples collected during tablet compression and tested for content uniformity did not meet United States Pharmacopeia (USP) requirements.

An object of the present invention is to provide a pharmaceutical composition in oral dosage form as a bilayer tablet which provides immediate release of a piperidinoalkanol compound and sustained release of a sympathomimetic drug that exhibits acceptable bioavailability of each compound. An additional object of the invention is to provide a pharmaceutical composition in bilayer tablet form of high integrity consisting of an immediate release form of a piperidinoalkanol compound and a sustained release form of a sympathomimetic drug, such that the tablet resists cracking on standing, has acceptable physical strength and provides acceptable content uniformity which meets USP requirements. A further object of the present invention is to provide a bilayer tablet which exhibits a dissolution profile of the piperidinoalkanol which is similar to that of ALLEGRA[®] 60 mg capsules and a dissolution profile of the sympathomimetic drug which is slower than that of SUDAFED[®] 120 mg tablets.

A novel pharmaceutical composition in the form of a bilayer tablet has now been found which provides efficient and immediate absorption, and bioavailability of a piperidinoalkanol, such as 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride, and efficient sustained release and bioavailability of a sympathomimetic drug, such as pseudoephedrine hydrochloride after oral administration thereof. In addition, the novel bilayer tablet of the present invention exhibits acceptable content uniformity under USP requirements, resists cracking on standing and has acceptable physical strength. Furthermore, the novel bilayer tablet of the present invention provides a dissolution profile of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride which is similar to that for ALLEGRA[®] 60 mg capsules and a dissolution profile for pseudoephedrine hydrochloride which is slower than that for SUDAFED 12 HOUR[®] 120 mg tablets.

SUMMARY OF THE INVENTION

The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,

5 (a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;

10 (i) carnauba wax in an amount of about 59 % to about 81% by weight of Formulation (A); and
(ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of Formulation (A);

wherein said first carrier base material provides a sustained release of the
15 sympathomimetic drug; and

(b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 30% by weight of Formulation (B) and a second carrier base material, the
20 second carrier base comprising a mixture of;

(i) a cellulose diluent in an amount of about 27% to about 73% by weight of Formulation (B);
(ii) pregelatinized starch in an amount of about 15% to about 30% by weight of Formulation (B);
25 (iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of Formulation (B); and
(iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of Formulation (B);

wherein said second carrier base material provides an immediate release of
30 the piperidinoalkanol or the pharmaceutically acceptable salt thereof.

The present invention further provides a pharmaceutical composition in the form of a bilayer tablet comprising,


(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;

(l) carnauba wax in an amount of about 59 % to about 81% by weight of Formulation (A); and

(ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of Formulation (A);

wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and

(b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol of the formula:



wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof, in an amount of about 15% to about 30% by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of;

(I) a cellulose diluent in an amount of about 27% to about 73% by weight of Formulation (B);

(ii) pregelatinized starch in an amount of about 15% to about 30% by weight of Formulation (B);

(iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of Formulation (B); and

(iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of Formulation (B);

wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.

5

In addition, the present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,

(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof in an amount of about 25% to about 33% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;

10

(i) carnauba wax in an amount of about 66% to about 74% by weight of Formulation (A); and


15

(ii) a suitable antiadherent in an amount of about 0.50% to about 1.50% by weight of Formulation (A);

wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and

(b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol of the formula;

20



wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof, in an amount of about 15% to about 24% by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of;

25


- (I) a cellulose diluent in an amount of about 43% to about 67% by weight of Formulation (B);
- (ii) pregelatinized starch in an amount of about 15% to about 24% by weight of Formulation (B);
- (iii) a suitable disintegrant in an amount of about 3.20% to about 4.80% by weight of Formulation (B); and
- (iv) a suitable lubricant in an amount of about 0.50% to about 1.00% by weight of Formulation (B);

wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

As used herein the terms "piperidinoalkanol compounds" and "piperidinoalkanol compounds and their pharmaceutically acceptable salts" refers to those compounds described by formulas (I), (II) and (III) which are disclosed in U.S. Patent Nos. 3,878,217, 4,254,129 and 4,285,957 the disclosure of each patent being incorporated herein by reference.

Piperidinoalkanol compounds of formula (I) are those which correspond to the formula;




Formula (I)

wherein R_1 is hydrogen or hydroxy; R_2 is hydrogen; or R_1 and R_2 taken together form a second bond between the carbon atoms bearing R_1 and R_2 ; n is a positive whole integer of from 1 to 3; Z is thienyl, phenyl or substituted phenyl wherein the substituents on the substituted phenyl may be attached at the ortho, meta or para positions of the unsubstituted phenyl ring and are selected from the group consisting of a halogen atom, a straight or branched lower alkyl chain of from 1 to 4 carbon

atoms, a lower alkoxy group of from 1 to 4 carbon atoms, a di(lower)alkylamino group, or a saturated monocyclic heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperizino, or pharmaceutically acceptable acid addition salts thereof.

5

Piperidinoalkanol compounds of formula (II) are those which correspond to the formula;




Formula (II)

wherein R_1 represents hydrogen or hydroxy; R_2 represents hydrogen; or R_1 and R_2 taken together form a second bond between the carbon atoms bearing R_1 and R_2 ; m is an integer of from 1 to 5; R_3 is $-CH_3$, or $-CH_2OH$; each A and B is hydrogen or hydroxy; with the provisos that at least one of A or B is hydrogen and one of A or B is other than hydrogen when R_3 is $-CH_3$; and pharmaceutically acceptable salts and individual optical isomers thereof.

10


Piperidinoalkanol compounds of formula (III) are those which correspond to the formula;



Formula (III)

wherein R_1 represents hydrogen or hydroxy; R_2 represents hydrogen; or R_1 and R_2 taken together form a second bond between the carbon atoms bearing R_1 and R_2 ; m is an integer of from 1 to 5; R_4 is $-\text{CO}_2\text{H}$ or $-\text{CO}_2\text{alkyl}$ wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy; with the proviso that at least one of A or B is hydrogen; and pharmaceutically acceptable salts and individual optical isomers thereof.


More specifically, 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride of formula (IIIa);



Formula (IIIa)

wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof, is a preferred piperidinoalkanol compound. The compound 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride wherein X is zero or one in formula (IIIa) is the most preferred piperidinoalkanol compound.

In addition, the free base of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid of formula (IIIb)



Formula (IIIb)

wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof, is also a preferred piperidinoalkanol compound.

Included within the scope of the present invention are the pseudomorphs and polymorphs of the hydrated and anhydrous free base of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid which can be prepared as disclosed in the International Publication No. WO 95/31437 published November 23, 1995. The free base of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid is readily prepared utilizing techniques and procedures well known to one of ordinary skill in the art. For example, the hydrochloride salt of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid is dissolved in methanol and treated with one equivalent of aqueous sodium bicarbonate. After stirring for approximately 5 to 30 minutes, the white solid is collected by filtration, rinsed with water and air dried to provide the dihydrate of the free base of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid.

Illustrative examples of straight or branched alkyl groups having from 1 to 4 carbon atoms referred to herein are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl. Illustrative examples of straight or branched alkyl groups having from 1 to 6 carbon atoms referred to herein are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopentyl, n-hexyl and cyclohexyl. Illustrative examples of lower alkoxy groups of from 1 to 4 carbon atoms referred to herein are methoxy,

ethoxy, propoxy, n-butoxy, isobutoxy, sec-butoxy and t-butoxy. The terms "halo", "halogen" or "halide" refers to a fluorine, chlorine, bromine or iodine atom.

The term "pharmaceutically acceptable salt" refers to those salts of formulas (I), (II), (III) and (IIIa) that are not substantially toxic at the dosage administered to achieve the desired effect and do not independently possess significant pharmacological activity. The salts included within the scope of this term are pharmaceutically acceptable acid addition salts of a suitable inorganic or organic acid. Suitable inorganic acids are, for example hydrochloric, hydrobromic, sulfuric and phosphoric acids. Suitable organic acids include carboxylic acids, such as acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, cyclamic, ascorbic, maleic, hydroxymaleic, dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranillic, cinnamic, salicylic, 4-aminosalicylic, 2-phenoxybenzoic, 2-acetoxybenzoic and mandelic acid, sulfonic acids, such as methanesulfonic, ethanesulfonic and β -hydroxyethanesulfonic acid. In addition, pharmaceutically acceptable salts include those salts of formulas (I), (II), (III) and (IIIa) formed with inorganic and organic bases, such as those of alkali metals, for example sodium, potassium and lithium, alkaline earth metals, for example calcium and magnesium, light metals of group IIIA, for example aluminum, organic amines, for example primary, secondary or tertiary amines, such as cyclohexylamine, ethylamine, pyridine, methylaminoethanol and piperazine. The salts are prepared by conventional means known by one of ordinary skill in the art as, for example, by treating a compound of formulas (I), (II), (III) or (IIIa) with an appropriate acid or base. Such salts can exist in either a hydrated or substantially anhydrous form. The preferred acid addition salts are those prepared from hydrochloric acid, sulfuric acid and tartaric acid.

The term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes geometric (cis/trans) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers). The term "chiral center" refers to a carbon atom to which four different groups are attached. The term "enantiomer", "enantiomeric" or "optical isomer" refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the optical isomer or enantiomer rotates the plane of polarized light in one direction and its mirror

image rotates the plane of polarized light in the opposite direction. The term "racemic mixture" or "racemic modification" refers to a mixture of equal parts of enantiomers and which is optically inactive. As used herein the prefixes "(+)" and "(-)" are employed to designate the sign of rotation of the plane of polarized light by the compound, with (+) meaning the compound is dextrorotatory and (-) meaning the compound is levorotatory.

The term "enantiomeric enrichment" refers to the increase in the amount of one enantiomer as compared to its corresponding opposite enantiomer. A convenient method of expressing enantiomeric enrichment achieved is the concept of "enantiomeric excess" or "ee", which is expressed by the following equation;

$$ee = \frac{E^1 - E^2}{E^1 + E^2} \times 100$$

in which E^1 is the amount of the first enantiomer and E^2 is the amount of the second corresponding enantiomer. For example, where the initial ratio of two enantiomers in a reaction is 50:50 (a racemic mixture) and the reaction produces enantiomeric enrichment with a final ratio of 90:10, then the ee with respect to the first enantiomer is 80%.

Various sympathomimetic drugs, such as pseudoephedrine, phenylephrine and phenylpropanolamine, are recognized by those skilled in the art as therapeutic agents effective in the relief of nasal congestion and are commonly administered concomitantly with antihistamines for relief of nasal congestion associated with allergic rhinitis. These sympathomimetic drugs are generally effective when administered orally in unit dosage form on a four times a day dosage schedule wherein the unit dosage form provides immediate release of the active medicament. For example, the recommended dosage for pseudoephedrine hydrochloride in adults is 60 mg every 6 hours (q.i.d.). In addition, unit dosage forms containing sympathomimetic drugs can be formulated to provide prolonged release of the active medicament so as to allow the effective daily dose to be administered on a less frequent dosage schedule. For example, the recommended dosage for pseudoephedrine hydrochloride in a sustained release formulation can be 120 mg twice daily (b.i.d.).

As used herein the term "sympathomimetic drug" refers to those sympathomimetic agents which are therapeutically effective in providing relief of nasal congestion in a patient suffering therefrom. These agents include, but are not limited to, pseudoephedrine, phenylephrine, and phenylpropanolamine. As is well
5 recognized and appreciated by those skilled in the art, these sympathomimetic drugs can be used according to the present invention as free amines or as pharmaceutically acceptable salts thereof.

A therapeutically effective decongestant amount of a sympathomimetic drug is that amount which produces the desired decongestant therapeutic response upon
10 oral administration and can be readily determined by one skilled in the art by use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective decongestant amount or dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the
15 response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

A therapeutically effective decongestant amount of a sympathomimetic drug
20 will vary from about 1 mg to about 200 mg. Preferred amounts will vary from about 5 mg to about 150 mg, with about 120 mg administered twice daily being most preferred.

It is understood that a therapeutically effective decongestant amount of a sympathomimetic drug is present in Formulation (A). The carrier base material of
25 Formulation (A) provides a prolonged or sustained release of the active medicament whereas the carrier base material of Formulation (B) provides an immediate release of the active medicament. As used herein the term "sustained release" refers to a property of the pharmaceutical composition wherein the absorption and bioavailability of the active medicament is maintained in a time-release pattern such that
30 therapeutically effective decongestant amounts of the sympathomimetic drug are bioavailable over an extended period of time. As used herein the term "immediate release" refers to a property of the pharmaceutical composition wherein the entire dose of active medicament is made bioavailable without substantial delay. A unit dose is that amount of the pharmaceutical composition which is individually

administered to a patient. In addition, it is appreciated by one of ordinary skill in the art that the pharmaceutical compositions of the present invention are useful as antihistamines, antiallergy agents, bronchodilators and in the treatment of urticaria.

As used herein, the term "patient" refers to a warm-blooded animal, such as a mammal, which is in need of an antihistamine, antiallergy agent, bronchodilator or requires treatment of urticaria. It is understood that humans, mice, rats and dogs are included within the term "patient".

As used herein, the term "cellulose diluent" includes microcrystalline cellulose, Avicel PH101, Avicel PH102, Avicel PH301, Avicel PH302, Avicel PH200, Avicel PH112, Avicel PH113, Avicel PH103, Avicel PH105 and the like. The preferred cellulose diluent is microcrystalline cellulose, Avicel PH101 and Avicel PH102, and the most preferred cellulose diluent is a combination of Avicel PH101 and Avicel PH102. It is especially preferred that the Avicel PH101 and Avicel PH102 mixture comprise about 12% Avicel PH101 and about 88% Avicel PH102.

As used herein, the term "suitable antiadherent" includes stearic acid, cetyl alcohol, stearyl alcohol, paraffin, white wax, glycerin, lanolin, talc, mineral oil and the like. The preferred suitable antiadherent is stearic acid.

As used herein, the term "suitable disintegrant" includes croscarmellose sodium, crospovidone, alginic acid, sodium alginate, methacrylic acid DVB, cross-linked PVP, microcrystalline cellulose, polacrillin potassium, sodium starch glycolate, starch, pregelatinized starch and the like. The preferred suitable disintegrant is croscarmellose sodium.

As used herein, the term "suitable lubricant" includes magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, hydrogenated vegetable oil and the like. The preferred suitable lubricant is magnesium stearate.

As used herein, the term "suitable glidant" includes silicon dioxide, talc and the like. The preferred suitable glidant is silicon dioxide.

The term "micronization" refers to the process of increasing the particle surface area of the piperidinoalkanol compounds or their pharmaceutically acceptable salts to greater than about 1.0 m²/g. Micronization of the piperidinoalkanol compounds of formulas (I) through (IIb) is readily performed by one of ordinary skill in the art, for example, as disclosed by T. Ortyl, et al. in WO 96/26726 published September 6, 1996.

The piperidinoalkanol compounds of formulas (I) through (IIIb) when micronized have a particle surface area of greater than about $1.0 \text{ m}^2/\text{g}$. The preferred particle surface area when micronized is about 2 to $10 \text{ m}^2/\text{g}$, the most preferred particle surface area when micronized is about 2.0 to $5 \text{ m}^2/\text{g}$ and the most especially preferred particle surface area of the piperidinoalkanol compounds of formulas (I) through (IIIb) when micronized is about $2.2 \text{ m}^2/\text{g}$. The piperidinoalkanol compounds of formulas (I) through (IIIb) which are not subjected to micronization have a particle surface area of less than about $1.0 \text{ m}^2/\text{g}$.

A therapeutically effective antihistaminic amount of a piperidinoalkanol compound of formulas (I) through (IIIb) is that amount which produces the desired therapeutic response (ie., antihistaminic, antiallergic, bronchodilatory effect, or reduction or elimination of urticaria) upon oral administration according to a single or multiple dosage regimen. A therapeutically effective antihistaminic amount of a piperidinoalkanol compound of formulas (I) through (IIIb) may vary over a wide range from about 0.1 mg to about 240 mg. The preferred therapeutically effective antihistaminic amount of a piperidinoalkanol compound of formulas (I) through (IIIb) will vary from about 20 mg to about 70 mg with about 60 mg administered twice daily being most preferred. The therapeutically effective antihistaminic amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances as described above for the sympathomimetic drugs.

It is understood that a therapeutically effective antihistaminic amount of a piperidinoalkanol compound of formulas (I) through (IIIb) is present in Formulation (B) of the pharmaceutical composition of the present invention. This Formulation (B) provides for immediate release of the active medicament.

In a preferred embodiment of the present invention with respect to the piperidinoalkanol in Formulation (B), about 60 mg of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidyl]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride is preferred. In a preferred embodiment of the present invention with respect to the sympathomimetic drug in Formulation (A), about 120 mg of pseudoephedrine hydrochloride is preferred.

As used herein a layered tablet is a tablet which is made up of two or more distinct layers or discrete zones of granulation compressed together with the

individual layers lying one on top of another. Layered tablets have the appearance of a sandwich because the edges of each layer or zone is exposed. Such conventional layered tablets are generally prepared by compressing a granulation onto a previously compressed granulation. The operation may be repeated to produce multilayered tablets of more than two layers. In a preferred embodiment of the present invention, the tablet consists of two layers wherein one layer is made from Formulation (A) and the other layer is made from Formulation (B), resulting in a bilayer tablet.

Formulation (A) and Formulation (B) of the pharmaceutical compositions of the present invention optionally may contain one or more other pharmaceutically acceptable excipients. These excipients are therapeutically inert ingredients such as are well known and appreciated in the art. As used herein the term "inert ingredient" refers to those therapeutically inert ingredients that are well known in the art of pharmaceutical science which can be used singly or in various combinations, and include, for example, binders, diluents, lubricants, glidants, sweetening agents, disintegrants, coloring agents, flavoring agents, antioxidants, solubilizing agents, coating agents and the like, as are disclosed in The United States Pharmacopeia, XXII, 1990, (1989 The United States Pharmacopeial Convention, Inc.), pages 1857-1859, which is incorporated herein by reference. For example, the following inert ingredients can be utilized singly or in various combinations; binders such as gelatin, polyvinylpyrrolidone (PVP), pregelatinized starch, povidone; diluents such as calcium carbonate, lactose, starch, microcrystalline cellulose, and the like; lubricants such as magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, hydrogenated vegetable oil and the like; glidants such as silicon dioxide, talc and the like; disintegrants such as alginic acid, methacrylic acid DVB, cross-linked PVP, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, starch, pregelatinized starch and the like; sweetening agents; coloring agents; flavoring agents; antioxidants; and the like.

Preferred compositions of the present invention are those wherein a cellulose diluent, pregelatinized starch, croscarmellose sodium and magnesium stearate are present with 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride in the immediate release layer of Formulation (B), and wherein carnauba wax, stearic acid and colloidal silicon dioxide

are present with pseudoephedrine hydrochloride in the sustained release layer of Formulation (A).

Preferred amounts of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride, cellulose diluent, pregelatinized starch, croscarmellose sodium and magnesium stearate in Formulation (B) are combined in amounts of from about 15% to about 30%, about 27% to about 73%, about 15% to about 30%, about 0.25% to about 6.00% and about 0.25% to about 2.00%, respectively, by weight of the composition, with about 16% to about 24%, about 43% to about 67, about 15% to about 24%, about 3.20% to about 4.80% and about 0.50% to about 1.00%, respectively, by weight of the composition, being most preferred, and about 17.09%, about 61.67%, about 17.09%, about 3.42% and about 0.75%, respectively, being most especially preferred.

Preferred amounts of pseudoephedrine hydrochloride, camauba wax, stearic acid flakes and colloidal silicon dioxide in Formulation (A) are combined in amounts of from about 18% to about 39%, about 59% to about 81%, about 0.25% to about 2.00%, and 0.00% to about 3.00%, respectively, by weight of the composition, with about 25% to about 33%, about 66% to about 74%, about 0.50% to about 1.50% and 0.00% to about 0.75%, respectively, by weight of the composition; being most preferred, and about 28.17%, about 70.42%, about 1.15% and about 0.25%, respectively, being most especially preferred.

The piperidinoalkanol compounds of formulas (I) through (IIIb) are readily prepared by one of ordinary skill in the art, for example, utilizing the techniques and procedures described in U.S. Patent Nos. 3,878,217, 4,254,129 and 4,285,957, which are hereby incorporated by reference, and International Application Number PCT/US93/02103 published October 28, 1993, WO 93/21156, International Application Number PCT/US94/05982, published January 5, 1995, WO 95/00480 and International Application Number WO 95/31437, published November 23, 1995.

The components of the pharmaceutical composition according to the present invention are brought together into a bilayer tablet for oral administration according to standard practice and procedures well known to one of ordinary skill in the art using conventional formulation and manufacturing techniques such as that described in the following examples. The following examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. The

reagents and starting materials are available to one of ordinary skill in the art. As used herein, the following terms have the indicated meanings: "rsd" refers to percent relative standard deviation; "kg" refers to kilograms; "g" refers to grams; "mg" refers to milligrams; "μg" refers to micrograms; "m²/g" refers to square meters per gram and is used as a measurement of particle surface area; "mmol" refers to millimoles; "L" refers to liters; "mL" refers to milliliters; "μL" refers to microliters; "cm" refers to centimeters; "M" refers to molar; "mM" refers to millimolar; "μM" refers to micromolar; "nM" refers to nanomolar; "eq" refers to equivalents; "N" refers to normal; "ppm" refers to parts per million; "°C" refers to degrees Celsius; "°F" refers to degrees Fahrenheit; "mm Hg" refers to millimeters of mercury; "kPa" refers to kilopascals; "psi" refers to pounds per square inch; "bp" refers to boiling point; "mp" refers to melting point; "dec" refers to decomposition; "HPLC" refers to high performance liquid chromatography; "RPM" refers to revolutions per minute; "hr" or refers to hours; "min" refers to minutes; "Kp" refers to Kilopond and "sec" refers to seconds.

EXAMPLE 1**Table 1. Composition of the Bilayer Tablet**

<u>Component</u>	<u>Weight</u> (mg/tablet)
<u>Immediate Release Layer</u>	
Piperidinoalkanol ¹	60.00
Microcrystalline Cellulose (Avicel PH101)	26.00
Pregelatinized Starch	60.00
Microcrystalline Cellulose (Avicel PH102)	190.5
Croscarmellose Sodium	12.00
Magnesium Stearate	2.633
Water, purified ²	(60.00)
Total Layer Weight	351.1
<u>Sustained Release Layer</u>	
Sympathomimetic Drug ³	120.0
Carnauba Wax	300.0
Stearic Acid Flakes	4.899
Colloidal Silicon Dioxide	1.065
Total Layer Weight	426.0
Total Core Tablet Weight	777.1
<u>Aqueous Coating Suspension</u>	
OPADRY [®] YS-1-7006	23.31
Water, purified ²	(170.9)
<u>Total Coated Tablet Weight</u>	800.4

¹4-[4-[4-(Hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride.

5 ²Removed during processing. Amount of water may be varied during processing if necessary to achieve the desired granulation characteristics.

³Pseudoephedrine hydrochloride.

Pilot Scale Process Used to Manufacture Bilayer Tablets.

The manufacture of the bilayer tablets at pilot scale is summarized as follows. The pseudoephedrine HCl granulation is manufactured by adding pseudoephedrine HCl to a melted mixture of carnauba wax and stearic acid with mixing. The liquid wax mixture is then poured onto trays in sheets and allowed to congeal as the wax cools. The congealed wax is then milled and blended with the colloidal silicon dioxide in an in-bin blender. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is manufactured using a high intensity granulator. The granulation is dried in a fluid bed drier and milled. The final blend components are added and blended in an in-bin blender. The bilayer tablets are compressed on a bilayer tablet press with the pseudoephedrine HCl granulation compressed as the first layer and 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend compressed as the second or top layer. The compressed tablets are then film coated with a clear coating in an Accela-Cota. Total process time required to manufacture film coated tablets is approximately 33 hours for a pilot scale batch of 130,000 tablets.

Pseudoephedrine HCL Granulation.

The quantities of components used to manufacture pseudoephedrine HCl granulation (80 kg batch size) are listed in Table 2. The carnauba wax is melted while continuously mixing at approximately 85 - 90°C in a 100 gallon Hamilton hot water jacketed stainless steel tank. The jacket water temperature is set at approximately 100°C. After all the carnauba wax is melted, stearic acid flakes are added and allowed to melt. Pseudoephedrine HCl is screened through a 30 mesh screen utilizing a Stokes Oscillating Granulator. The screened pseudoephedrine HCl is slowly added to the wax melt while continuously mixing with a Lightnin propeller type mixer. The temperature of the melt is held at approximately 90°C during pseudoephedrine HCl addition. Once all the screened pseudoephedrine HCl is added to the melted wax, the temperature is raised to 92°C and continuously mixed for 10 minutes. Approximate process time to manufacture pseudoephedrine HCl / liquid wax suspension is 5 hours.

The pseudoephedrine HCl / liquid wax suspension is then dispensed onto stainless steel trays to a thickness of approximately 1/4 inch and held at room temperature until solidified and cool to touch, approximately 2 hours. The solidified pseudoephedrine HCl wax matrix is stored in polyethylene lined fiber drums at room temperature for a minimum of 12 hours prior to milling to ensure that the wax matrix is adequately cooled.

The congealed wax is milled with the knives forward, at 2500 rpm, through a Fitzmill equipped with a #0065 drilled holed screen. The milled pseudoephedrine HCl granulation is added to a 200 Liter In-Bin Blending Tote. The required amount of colloidal silicon dioxide is screened through a 20 mesh hand screen and added to the 200 Liter Tote. The components of the tote bin are mixed for 70 revolutions (counts) at 18 rpm using a CMS In-Bin Blender. The final blend is stored in polyethylene lined fiber drums until needed for compression. Approximate process time for milling and blending steps is 1 hour.

4-[4-[4-(Hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid Hydrochloride Granulation and Final Blend.

Table 3 lists the ingredients and quantities utilized in manufacturing the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation and the final blend. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is prepared utilizing a Fielder PMA 300 Liter High Shear Mixer/Granulator. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride, croscarmellose sodium, pregelatinized starch and microcrystalline cellulose (Avicel PH101) are added to the fielder bowl and dry blended for 5 minutes with the impeller set at 110 RPM and the chopper off. The purified water is then added to the dry mix at a rate of 5.7 kg/min with the impeller speed set at 110 RPM and the chopper at 3600 RPM. The granulation is mixed for 30 seconds after the water addition is completed.

The granulation is divided into approximately equal halves and dried as two sub-batches in a Glatt Fluid Bed Dryer GPCG 30. The inlet air temperature is maintained at 80°C and the dewpoint is set at 9°C. The process air flow is set at 1050 m³/hr initially and gradually reduced over the drying time to 550 m³/hr. The

granulation is dried to a moisture content of 2-3% as determined by a Computrac set at 125°C. The ending product temperature is approximately 65°C and the drying time is approximately 160 minutes total drying time. The final moisture content of the dried granulation is approximately 2.5%.

5 Each sub-batch of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is separately milled through a 1532-0050 drilled holed screened using a Fitzmill set at medium speed with the knives in the forward position. Both sub-batches of granulation are blended together for 3 minutes in a 5 cubic foot Patterson Kelly V-Blender. The
10 milled blends are stored in polyethylene lined fiber drums until needed for final blending. Approximate process time through the milling and blending step for the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is 8 hours.

The formulation for the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is listed in
15 Table 3. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is manufactured using a 200 Liter In-Bin Blending Tote. The microcrystalline cellulose (Avicel PH102), croscarmellose sodium (Ac-Di-Sol) and the milled 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation
20 from above are charged into the tote bin. The components are blended for 140 revolutions (counts) at 18 rpm. Magnesium stearate is screened through a 30 mesh hand screen and added to the 200 liter tote bin and is blended for 70 counts at 18 rpm. The final blend is stored in polyethylene lined fiber drums until needed for
25 compression. Approximate process time for final blend process is 0.5 hours.

Bilayer Tablet Compression.

The bilayer tablet batch is manufactured utilizing a 35 Station Manesty BB4 Bi-Layer Rotary Tablet Press. Tablets are compressed using 0.3125 inch x 0.7500 inch capsule shaped standard concave tooling. The tablet batch size is 180,000 tablets manufactured from 76.7 kg of pseudoephedrine HCl granulation and 63.2 kg of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend. The average press speed is approximately 640 tablets per minute. The total compression time is approximately 5 hours.

The pseudoephedrine HCl granulation is compressed into the first layer at a target weight of 426 mg per tablet. The average target tablet hardness (Key Hardness Tester, tablet tested across width) for the pseudoephedrine HCl layer is about 8 kp. The second layer which consists of the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is added to the first layer for a total tablet target weight of 777.1 mg (which is equivalent to 351.1 mg / tablet of the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend). The bilayer tablet is compressed to a target hardness of about 20 kp (Key hardness Tester, tablet tested across length).

Coating

The compressed bilayer tablets are coated in a 48 inch Accela-Cota (101.0 kg uncoated tablets, approximately 130,000 tablets) using a two gun spray system at a pan speed of 10.5 rpm. The tablets are coated using a 12% w/w coating solution of clear coat OPADRY® YS-1-7006 which contains hydroxypropyl methylcellulose and polyethylene glycol. The coating suspension is filtered through a 60 mesh screen prior to use. The tablets are coated with 25.25 kg of coating solution. The tablets are coated at an outlet air temperature of approximately 41°C with a range of 39.6 - 41.9°C. The inlet air temperature generally ranges from 55 - 62°C and a supply air flow rate of 1700 - 1800 cubic feet per minute is used. The coating solution flow rate is started at approximately 230 g/min and increased periodically to reach a final spray rate of approximately 390 g/min. An atomizing air pressure of 50 psi is used during spraying of the coating solution. The total coating process time is approximately 1.5 hours.

Table 2. Pseudoephedrine HCl Granulation Formulation Pilot Scale.

Component	Quantity (mg/gm)	Quantity (kg/80 kg Batch Size)
Pseudoephedrine HCl	281.7	22.54
Carnauba Wax, NF	704.3	56.34
Stearic Acid Flakes, NF	11.50	0.920
Colloidal Silicon Dioxide, NF	2.50	0.200

Table 3. Piperidinoalkanol¹ Final Blend Formulation Pilot Scale.

Component	Quantity (mg/gm)	Quantity (kg/65 kg Blend Batch Size)
*** Piperidinoalkanol ¹ Granulation	438.6	28.51
Microcrystalline Cellulose (Avicel PH102)	542.5	35.26
Croscarmellose, Sodium	11.40	0.741
Magnesium Stearate	7.5	0.4875
*** Piperidinoalkanol ¹ Granulation		
Component	Quantity (mg/gm)	Quantity (kg/60 kg Granulation)
Piperidinoalkanol ¹ Drug Substance	389.6	23.38
Croscarmellose, Sodium	51.95	3.117
Pregelatinized Starch	389.6	23.38
Microcrystalline Cellulose (Avicel PH101)	168.8	10.13
Water, Purified USP ²	389.6	23.38

¹ 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride.

² Water is removed during the process and does not appear in the final product. The amount of water may be varied to achieve suitable granulation.

Commercial Scale Process Used to Manufacture the Bilayer Tablets.

Manufacture of the bilayer tablets at commercial scale is summarized as follows. Pseudoephedrine HCl granulation is manufactured by adding
5 pseudoephedrine HCl to melted carnauba wax with mixing. The liquid wax mixture is pumped through a droplet forming stainless steel tube (Rotoform[®] unit) onto a rotating stainless steel chilled belt. The congealed droplets of wax (pastilles) are discharged off the end of the rotating belt. The pastilles are then milled and blended with the colloidal silicon dioxide in an in-bin blender. The 4-[4-[4-
10 (hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic granulation is manufactured using a high intensity granulator. The granulation is dried in a fluid bed drier and milled. The final blend components are added and blended in an in-bin blender. The bilayer tablets are compressed on a two layer tablet press with the pseudoephedrine HCl granulation compressed as the first layer
15 and 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend compressed as the second or top layer. The compressed tablets are then film coated with a clear coating in an Accela-Cota. Total process time required to manufacture film coated tablets is approximately 50 hours for a commercial scale batch of 1,374,000 tablets.

Pseudoephedrine HCl Granulation.

The quantities of components used to manufacture pseudoephedrine HCl granulation (600 kg batch size) are listed in Table 4. The carnauba wax is melted while continuously mixing at approximately 85 - 90°C in a 300 gallon jacketed
25 stainless steel tank. The jacket water temperature is set at approximately 120°C. After all the carnauba wax is melted, stearic acid flakes are added and allowed to melt. Pseudoephedrine HCl is screened through a 30 mesh screen utilizing a Stokes Oscillating Granulator (Model 43-6). The screened pseudoephedrine HCl is slowly added to the wax melt while continuously mixing with a propeller type mixer (Sew-
30 Eurodrive mixer). The temperature of the melt is held at approximately 92°C during pseudoephedrine HCl addition. Once all the screened pseudoephedrine HCl is added to the melted wax, the temperature is raised to 95°C and continuously mixed for a minimum of 20 minutes and mixing is continued until completion of the wax

congealing step and the temperature is maintained at 95°C during the congealing step. Approximate process time to manufacture the pseudoephedrine HCl / liquid wax suspension is 6 hours.

The pseudoephedrine HCl / liquid wax suspension is pumped using a hot water jacketed positive displacement pump (Wauakasha Model 6) through 3/8 inch (internal diameter) hot water (110°C) jacketed stainless steel lines to a droplet forming stainless steel tube (Sandvik Rotoform® 3000, Model LV). A 20 mesh screen is placed in line of the liquid wax suspension feed to protect the Rotoform®. The Rotoform® has a Shell Bore of 2.0 mm, Shell Pitch of 8.0 mm, a Triangular Offset Shell Geometry and a Bar Slot Width of 6.0 mm. The Rotoform® is heated with 110°C hot water through the fixed cylindrical stator body which has a 1 inch recess for liquid wax flow through its entire body.

The rotating Rotoform® unit is positioned over the rotating Sandvik stainless steel chilled belt such that droplets of the liquid wax mixture fall onto the moving belt. The Sandvik stainless steel chilled belt is utilized for the wax cooling (congealing) process. The belt is chilled with water sprayed from the bottom side of the belt. The stainless steel chilled belt is 32 inches wide and has a cooling zone 24 feet long. The front pulley on the belt is heated to 65°C. The Rotoform® unit is set approximately 2 mm above the moving belt. A belt speed and Rotoform® speed of 70 feet / minute are used along with a cooling water temperature of 15°C. The pseudoephedrine HCl / liquid wax suspension is pumped at a rate of approximately 5 kg/min onto the belt. The congealed droplets of wax (pastilles) approximately 5 mm in diameter are discharged off the end of the rotating belt at a temperature of approximately 20°C. The congealed wax pastilles are milled with the knives forward, at 3000 rpm, through a Fitzpatrick DAS06 mill equipped with a 0065 drilled holed screen. Approximate process time for the wax congealing and milling step is 3 hours.

The milled pseudoephedrine HCl granulation is charged into an 1800 Liter In-Bin Blending Tote (Gallay). The colloidal silicon dioxide is screened through a 20 mesh hand screen and added to the 1800 Liter Tote. The contents of the bin are blended for 140 revolutions (counts) at 14 rpm using a CMS In-Bin Blender. The final blend is stored in the tote bin until needed for tablet compression. The approximate process time for the pseudoephedrine HCl granulation blend step is 1 hour.

4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid Hydrochloride Granulation and Final Blend.

Table 5 lists the ingredients and quantities utilized in manufacturing the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation and the final blend. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is prepared utilizing a Fielder PMA 800 Liter High Shear Mixer/Granulator. The 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride, croscarmellose sodium, pregelatinized starch and microcrystalline cellulose (Avicel PH101) are added to the fielder bowl and dry blended for 5 minutes with the impeller set at 116 RPM and the chopper off. The purified water is then added to the dry mix at a rate of 15 kg/min with the impeller speed set at 116 RPM and the chopper at 1800 RPM. After the water is added, the granulation is mixed for a total of 6 minutes from the start of water addition. The chopper speed is increased to 2800 RPM with the impeller set at 116 RPM and the granulation is mixed an additional 60 seconds and then discharged from the granulator into the fluid bed drier product bowl.

The granulation is dried in a Glatt Fluid Bed Dryer GPCG 300. The inlet air temperature is maintained at 80°C and the dewpoint is set at 9°C. The process air flow is set at 3800 m³/hr initially and gradually reduced over the drying time to 2900 m³/hr. The granulation is dried to a moisture content of 2-4% as determined by a Computrac set at 115°C. The ending product temperature is approximately 66°C and the drying time is approximately 100 minutes total drying time. The final moisture content of the dried granulation is approximately 3.0%. The dried 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation is milled through a 1532-0050 drilled holed screened using a Fitzmill set at medium speed with the knives in the forward position. The granulation is milled into an 1800 Liter In-Bin Blending Tote (Gallay). The approximate process time for the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride granulation through the milling step is 5 hours.

The formulation for the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is listed in

Table 4. The microcrystalline cellulose (Avicel PH102) and croscarmellose sodium (Ac-Di-Sol) are charged into the tote bin containing the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride milled granulation. The contents are blended for 140 revolutions (counts) at 14 rpm using a CMS In-Bin Blender. Magnesium stearate is screened through a 30 mesh hand screen and added to the 1800 liter tote bin and the contents are blended for 70 counts at 14 rpm using a CMS In-Bin Blender. The final blend is stored in the tote bin until needed for tablet compression. The approximate process time for the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is 1 hour.

Bilayer Tablet Compression.

The bilayer tablet batch is manufactured utilizing a 51 Station Hata Bi-Layer Rotary Tablet Press, Model HT-HX51LD-U. Tablets are compressed using 0.3125 inch x 0.7500 inch capsule shaped standard concave tooling. The tablet batch size is 1,374,000 tablets manufactured from 585.3 kg of pseudoephedrine HCl granulation and 482.4 kg of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend. The average press speed is approximately 1200 tablets per minute. The total compression time is approximately 19 hours. Both the pseudoephedrine HCl granulation and the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend are fed to the press from the tote bins used for blending by using a Gallay bin drop station.

The pseudoephedrine HCl granulation is compressed into the first layer at a target weight of 426 mg per tablet. The powder feeder for the pseudoephedrine HCl granulation is operated at 75%. The target thickness for the pseudoephedrine HCl layer is 0.162 inches with an average tablet hardness (Key Hardness Tester, tablet tested across width) of about 8 kp. The second layer which consisted of the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend is added to the first layer for a total tablet target weight of 777.1 mg (which is equivalent to 351.1 mg / tablet of the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride final blend). The powder feeder for the 4-[4-[4-

(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride blend is operated at 100%. The bilayer tablet is compressed to a target thickness of 0.240 inches with an average hardness of about 20 kp (Key hardness Tester, tablet tested across length).

5

Coating

The compressed bilayer tablets are coated in a 48 inch Accela-Cota as 10 sub-batches of approximately 106.8 kg uncoated tablets (approximately 137,400 tablets) using a three gun spray system at a pan speed of 11 RPM. The tablets are coated using a 12% w/w coating solution of clear coat OPADRY® YS-1-7006 which contains hydroxypropyl methylcellulose and polyethylene glycol. The tablets are coated with 26.70 kg of coating solution. The tablets are coated at an outlet air temperature of approximately 41°C with a range of 39.0 - 41.0°C. The inlet air temperature generally ranged from 55 - 62°C and a supply air flow rate of 1700 - 1900 cubic feet per minute is used. The coating solution flow rate is started at approximately 250 g/min and increased periodically to reach a final spray rate of approximately 375 - 400 g/min. An atomizing air pressure of 60 psi is used during spraying of the coating solution. The total coating process time is 1.5 hours per coating sub-batch. Process time for 10 sub-batches is 15 hours.

20

Table 4. Pseudoephedrine HCl Wax Granulation Formulation Commercial Scale.

Component	Quantity (mg/gm)	Quantity (kg/600 kg Batch Size)
Pseudoephedrine HCl	281.7	169.0
Carnauba Wax, NF	704.3	422.6
Stearic Acid Flakes, NF	11.50	6.9
Colloidal Silicon Dioxide, NF	2.50	1.5

Table 5. Piperidinoalkanol¹ Final Blend Formulation Commercial Scale.

Component	Quantity (mg/gm)	Quantity (kg/482.8 kg Blend Batch Size)
*** Piperidinoalkanol ¹ Granulation	438.6	211.8
Microcrystalline Cellulose (Avicel PH102)	542.5	261.9
Croscarmellose, Sodium	11.40	5.504
Magnesium Stearate	7.5	3.621
*** Piperidinoalkanol ¹ Granulation		
Component	Quantity (mg/gm)	Quantity (kg/211.8 kg Granulation)
Piperidinoalkanol ¹ Drug Substance	389.6	82.52
Croscarmellose, Sodium	51.95	11.00
Pregelatinized Starch	389.6	82.52
Microcrystalline Cellulose (Avicel PH101)	168.8	35.75
Water, Purified USP ²	390.0	82.60

¹4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride.

²Water is removed during the process and does not appear in the final product. The amount of water may be varied to achieve suitable granulation.

Method for Determining Content Uniformity.

Content uniformity is determined by one of ordinary skill in the art utilizing known techniques and procedures. One of ordinary skill in the art for example, may utilize an isocratic HPLC procedure wherein an Alltech Adsorbosphere XL SCX, 5 μ m (50 mm x 4.6 mm ID) strong base cation exchange column followed in series by a Zorbax SB-Phenyl, 5 μ m (250 mm x 4.6 mm ID) reverse phase column is employed. A mobile phase consisting of 65:35 v/v methanol:buffer (0.050 M sodium acetate and

0.075 M 1-octanesulfonic acid, sodium salt, pH = 4.60 by adjusting with acetic acid) is pumped through the column at a flow rate of 1.5 mL/min. The column temperature is maintained at 35°C. Standards and samples are injected onto the column using a 20 µL injection volume followed by UV detection at 215 nm.

5 Ten individual tablet samples are prepared as follows. One tablet is placed into a 100-mL volumetric flask and 60.0 mL of methanol is added. The flask is stoppered and shaken for 60 minutes on a mechanical shaker set at high speed. After the shaking period, the flask is placed into an Ultrasonic-Heating Bath and sonicated at 40°C for 60 minutes. During the 60 minute sonication period, the flask is
10 vigorously shaken by hand every 15 minutes to help break up the tablets. After the initial 60 minute sonication period, 35 mL of the buffer (0.050 M sodium acetate and 0.075 M 1-octanesulfonic acid, sodium salt, pH = 4.60 by adjusting with acetic acid) is added into the flask, mixed, then placed into an Ultrasonic-Heating Bath for a second time and sonicated at 40°C for 60 minutes. During the second 60 minute sonication
15 period, the flask is vigorously shaken by hand every 15 minutes to help break up the tablets. After the second sonication period the flasks are removed from the sonicator and allowed to cool to room temperature. After reaching room temperature, the flask is shaken/mixed, then the majority of the floating excipients are poured off into a waste container. Approximately 6-8 mL of the remaining sample solution is filtered
20 into a small beaker using a 0.45 µm Whatman GD/X filter, yielding a Sample Solution I. Using a volumetric pipette, 4.0 mL of the Sample Solution I is pipetted into a 50-mL volumetric flask, diluted to volume with mobile phase yielding Sample Solution II, and injected into the HPLC system. Peak areas for pseudoephedrine and 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic
25 acid are determined and the percent of label claim is calculated for each active.

Table 6. Uncoated Bilayer Tablet In-Process Content Uniformity; 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid Hydrochloride Content Uniformity, n = 10.

Sampling Time During Compression	Mean % Label Claim	rsd	Range % Label Claim
Beginning	100.6	2.0	98.1 to 103.1
1 hour	101.5	3.5	95.5 to 106.0
3 hours	100.1	2.5	96.2 to 103.2
4 hours	100.0	3.2	96.5 to 105.2
5 hours/ending	91.9	2.9	95.4 to 104.4

5

Table 7. Uncoated Bilayer Tablet In-Process Content Uniformity; Pseudoephedrine Hydrochloride Content Uniformity, n = 10.

Sampling Time During Compression	Mean % Label Claim	rsd	Range % Label Claim
Start	101.8	1.1	100.1 to 103.3
1 hour	100.8	1.8	98.7 to 104.8
3 hours	100.6	1.0	99.5 to 102.4
4 hours	100.0	3.7	96.5 to 109.7
5 hours/ending	102.0	1.1	100.5 to 104.6

Tables 6 and 7 provide the content uniformity for 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride and pseudoephedrine hydrochloride respectively. Good content uniformity ensures that every tablet contains the amount of drug substance intended with little variation among tablets within a batch. In order to establish good content uniformity, the United States Pharmacopeia 23, The United States Pharmacopeial Convention, Inc., Rockville, MD, page 1838, sets a deviation of less than or equal to 6% and all individual tablets must lie within 85.0% to 115.0% of label claim for a sample of 10 tablets. As revealed above, the present invention provides a pharmaceutical composition which exhibits good content uniformity wherein the largest variation observed for 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-

hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride was 3.5% RSD at the 1 hour sample and for pseudoephedrine hydrochloride was 3.7% RSD at the 3 hour sample.

5 Dissolution Method.

Dissolution profiles are determined by one of ordinary skill in the art utilizing known techniques and procedures. For example, dissolution testing is performed in 900 mL of 0.001 N HCl (pH=3.00) maintained at 37°C using USP paddle (Apparatus 2, see for example Remington's Pharmaceutical Sciences, Mack Publishing
10 Company, (1990), Eighteenth Edition, pages 595-596) method with a rotation speed of 50 RPM. Aliquots of each dissolution test solution are collected and filtered through 45 μ m polyethylene sampling filters at the sampling intervals of 15, 30, 45, 60, 180, 300, 420, and 720 minutes. Each aliquot of the collected dissolution sample solution is analyzed using an isocratic HPLC procedure utilizing a Whatman Partisil
15 10 SCX (250 mm x 4.6 mm ID) strong base cation exchange column. A mobile phase consisting of 45:55 v/v acetonitrile:buffer (0.05 M sodium phosphate, pH = 2.00 \pm 0.05) is pumped through the column at a flow rate of 1.0 mL/min. The column temperature is maintained at ambient room temperature. Standards and samples are injected onto the column using a 10 μ L injection volume followed by UV detection at
20 210 nm. Peak areas for pseudoephedrine and 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid are determined and the percent of label claim released at each time interval is calculated for each active.

Table 8. Uncoated Bilayer Tablet Dissolution Profile for 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid Hydrochloride Dissolution.

Sampling Time During Compression	0.25 h Mean (rsd)	0.5 h Mean (rsd)	1.0 h Mean (rsd)
Start	89.6 (3.7)	95.9 (2.4)	97.7 (2.6)
1 hour	88.2 (4.2)	93.1 (3.7)	96.0 (3.1)
3 hours	82.4 (9.1)	88.0 (6.9)	92.1 (4.9)
4 hours	96.3 (2.5)	98.3 (2.4)	99.2 (2.4)
5 hours/end	91.9 (3.6)	94.9 (2.9)	96.6 (2.2)

5 Table 9. Uncoated Bilayer Tablet Dissolution Profile for Pseudoephedrine Hydrochloride.

Sampling Time During Compression	0.25 h Mean (rsd)	0.5 h Mean (rsd)	1 h Mean (rsd)	3 h
Start	20.9 (2.8)	29.9 (1.6)	41.4 (1.6)	67.5 (1.8)
1 hour	21.0 (1.9)	29.7 (2.2)	41.5 (2.2)	67.4 (1.5)
3 hour	20.9 (2.6)	29.5 (1.0)	41.2 (1.7)	67.1 (1.0)
4 hour	21.0 (2.0)	29.6 (1.5)	41.3 (1.1)	67.4 (1.2)
5 hours/end	21.4 (1.8)	30.1 (1.5)	41.7 (1.6)	68.0 (1.9)

Table 9 continued.

Sampling Time During Compression	5 h Mean (rsd)	7 h Mean (rsd)	10 h Mean (rsd)	12 h Mean (rsd)
Start	81.2 (1.2)	89.2 (1.0)	93.8 (1.0)	94.9 (1.2)
1 hour	80.3 (1.1)	88.9 (1.2)	93.7 (1.2)	95.1 (1.1)
3 hour	80.3 (1.1)	88.2 (1.2)	93.0 (1.0)	94.5 (0.9)
4 hour	80.6 (0.9)	87.8 (0.9)	92.8 (1.0)	94.4 (0.9)
5 hours/end	81.3 (1.7)	88.4 (1.6)	93.7 (1.5)	95.3 (1.5)

Table 10. Dissolution of SUDAFED 12 HOUR® Tablets;
Percent of Label Claim Released.

	Percent Pseudoephedrine Dissolved (% of LC)								
Test Media	.25 Hr	0.5 Hr	0.75 Hr	1.0 Hr	3.0 Hr	5.0 Hr	7.0 Hr	10 Hr	12 Hr
1 mm HCl	14.5	25.9	34.5	41.3	71.8	87.2	95.7	N/A	101.1

Table 11. Dissolution of ALLEGRA® capsules in 1 mm HCl Media;
Percent of Label Claim Released.

0.25 Hr	0.50 Hr	0.75 Hr	1.0 Hr
81.1 %	87.5 %	90.7 %	92.8 %

Tables 8 and 9 provide the dissolution profiles for 4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride and pseudoephedrine hydrochloride respectively. Tables 10 and 11 provide the dissolution profiles for SUDAFED 12 HOUR® Tablets and ALLEGRA® capsules respectively.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition in the form of a bilayer tablet comprising,

(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;

(i) carnauba wax in an amount of about 59% to about 81% by weight of Formulation (A); and

(ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of Formulation (A);

wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and

(b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 30% by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of;

(i) a cellulose diluent in an amount of about 27% to about 73% by weight of Formulation (B);


(ii) pregelatinized starch in an amount of about 15% to about 30% by weight of Formulation (B);

(iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of Formulation (B); and

(iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of Formulation (B);

wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of claim 1 wherein the piperidinoalkanol is of the formula;



5 wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof.


3. A pharmaceutical composition in the form of a bilayer tablet comprising,

10 (a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof in an amount of about 25% to about 33% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;

15 (i) carnauba wax in an amount of about 66% to about 74% by weight of Formulation (A); and
(ii) a suitable antiadherent in an amount of about 0.50% to about 1.50% by weight of Formulation (A);

wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and

20 (b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol of the formula;



wherein X is a number ranging from about zero to about 5, and the individual optical isomers thereof, in an amount of about 15% to about 24% by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of;

- (i) a cellulose diluent in an amount of about 43% to about 67% by weight of Formulation (B);
- (ii) pregelatinized starch in an amount of about 15% to about 24% by weight of Formulation (B);
- (iii) a suitable disintegrant in an amount of about 3.20% to about 4.80% by weight of Formulation (B); and
- (iv) a suitable lubricant in an amount of about 0.50% to about 1.00% by weight of Formulation (B);

wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition according to claim 1 wherein a suitable glidant is included in the first carrier base material of Formulation (A) in an amount of 0.00% to about 3.00% by weight of Formulation (A).

5. A pharmaceutical composition according to claim 1 wherein a suitable glidant is included in the first carrier base material of Formulation (A) in an amount of 0.00% to about 0.75% by weight of Formulation (A).

6. A pharmaceutical composition according to claim 5 wherein the suitable glidant is colloidal silicon dioxide.

7. A pharmaceutical composition according to either claim 3 or claim 6 wherein the sympathomimetic drug is pseudoephedrine hydrochloride.

8. A pharmaceutical composition according to claim 7 wherein the suitable antiadherent of Formulation (A) is stearic acid, and in Formulation (B), the suitable disintegrant is croscarmellose sodium and the suitable lubricant is magnesium stearate.

9. A pharmaceutical composition according to claim 8 wherein the pseudoephedrine hydrochloride, carnauba wax, stearic acid and colloidal silicon dioxide of Formulation (A) are combined in amounts of about 28.17%, about 70.42%, about 1.15% and about 0.25% respectively, by weight of the composition of Formulation (A), and the piperidinoalkanol, cellulose diluent, pregelatinized starch, croscarmellose sodium and magnesium stearate of Formulation (B) are combined in amounts of about 17.09%, about 61.67%, about 17.09%, about 3.42% and about 0.75% respectively, by weight of the composition of Formulation (B).

10. The pharmaceutical composition according to claim 9 wherein the piperidinoalkanol is 4-[4-[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic acid hydrochloride.

11. The pharmaceutical composition according to claim 10 wherein the cellulose diluent comprises a combination of Avicel PH101 and Avicel PH102.

12. The pharmaceutical composition according to claim 11 wherein the
5 combination of Avicel PH101 and Avicel PH102 comprises about 12% Avicel PH101 and about 88% Avicel PH102.

13. The pharmaceutical composition according to claim 12 wherein the 4-[4-
[4-(hydroxydiphenylmethyl)-1-piperdiny]-1-hydroxybutyl]- α,α -dimethylbenzeneacetic
10 acid hydrochloride is present in an amount of about 60 mg and the pseudoephedrine hydrochloride is present in an amount of about 120 mg.

14. A pharmaceutical composition according to claim 13 wherein the bilayer tablet is coated with a suitable coating agent.

15. A pharmaceutical composition according to claim 14 wherein the bilayer tablet is coated with OPADRY® YS-1-7006.

16. A pharmaceutical composition according to claim 15 wherein the
20 OPADRY® YS-1-7006 is present in amount of about 2.9 % by weight of the composition.

17. A pharmaceutical composition according to claim 13 wherein the bilayer tablet has a hardness of about 15 kp to about 25 kp.

INTERNATIONAL SEARCH REPORT

II. National Application No

PCT/US 98/15237

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/20 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 348 683 A (MERRELL DOW PHARM. INC., U.S.A.) 3 January 1990 cited in the application see the whole document ---	1-17
A	EP 0 311 067 A (MERRELL DOW PHARM. INC., U.S.A.) 12 April 1989 cited in the application see the whole document ---	1-17
A	EP 0 310 999 A (MERRELL DOW PHARM. INC., U.S.A.) 12 April 1989 cited in the application see the whole document ---	1-17
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 1998

Date of mailing of the international search report

03/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/15237

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 26726 A (HOECHST MARION ROUSSEL INC., U.S.A.) 6 September 1996 cited in the application see the whole document ----	1-17
A, P	CHEMICAL ABSTRACTS, vol. 129, no. 3, 20 July 1998 Columbus, Ohio, US; abstract no. 32342, XP002081560 see abstract & JP 10 114655 A (KYOWA HAKKO KOGYO CO. LTD., JP) 6 May 1998 -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. .national Application No

PCT/US 98/15237

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 348683	A	03-01-1990	US 4999226 A	12-03-1991
			AU 615751 B	10-10-1991
			AU 3580089 A	07-12-1989
			CA 1327011 A	15-02-1994
			CN 1038021 A	20-12-1989
			DK 265489 A	02-12-1989
			FI 892640 A,B	02-12-1989
			GR 3003477 T	17-02-1993
			IE 61182 B	05-10-1994
			JP 2028111 A	30-01-1990
			JP 2757017 B	25-05-1998
			PT 90689 A,B	29-12-1989
EP 311067	A	12-04-1989	AU 2345988 A	20-04-1989
			CA 1314485 A	16-03-1993
			CN 1032738 A	10-05-1989
			DE 3874072 A	01-10-1992
			DK 559088 A	08-04-1989
			FI 884545 A,B	08-04-1989
			GR 3005542 T	07-06-1993
			IE 61130 B	05-10-1994
			JP 1128925 A	22-05-1989
			JP 2722219 B	04-03-1998
			KR 9607748 B	12-06-1996
			NO 176746 B	13-02-1995
			PH 26155 A	18-03-1992
			PT 88682 A,B	01-11-1988
			US 4996061 A	26-02-1991
EP 310999	A	12-04-1989	AR 240018 A	31-01-1990
			AU 2346088 A	10-08-1989
			CA 1316458 A	20-04-1993
			CN 1032739 A,B	10-05-1989
			DE 3873011 A	27-08-1992
			DK 559288 A	08-04-1989
			ES 2051809 T	01-07-1994
			FI 884611 A,B,	08-04-1989
			GR 3005787 T	07-06-1993
			IE 60323 B	29-06-1994
			JP 1128924 A	22-05-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. national Application No

PCT/US 98/15237

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 310999 A		JP 2722220 B	04-03-1998
		KR 9607753 B	12-06-1996
		PT 88681 A,B	01-11-1988
		US 4929605 A	29-05-1990
WO 9626726 A	06-09-1996	AU 4909896 A	18-09-1996
		CA 2213700 A	06-09-1996
		CN 1176599 A	18-03-1998
		EP 0812195 A	17-12-1997
		FI 973518 A	27-08-1997
		NO 973938 A	28-10-1997
		US 5738872 A	14-04-1998